We have located links that may give you full text access.
CLINICAL TRIAL
JOURNAL ARTICLE
RANDOMIZED CONTROLLED TRIAL
RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Macular Photocoagulation Study Group.
Archives of Ophthalmology 1993 September
OBJECTIVES: To assess the visual prognosis of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization (CNV), and to determine the risk of CNV developing in fellow eyes that were initially unaffected.
DESIGN, PATIENTS, AND SETTING: Five-year prospective follow-up study of fellow eyes of 228 patients enrolled in a randomized clinical trial of laser photocoagulation of extrafoveal CNV. Visual acuity was measured and macular photographs were taken at 6-month intervals.
MAIN OUTCOME MEASURES: Five-year change in visual acuity of fellow eyes from baseline, incidence of legal blindness (visual acuity of < or = 20/200 in the better eye), and cumulative incidence of CNV in fellow eyes free of neovascular maculopathy at the time of study enrollment.
RESULTS: Photographically documented CNV developed in 33 (26%) of 128 fellow eyes that were initially free of neovascular maculopathy, and was associated with poor visual acuity at the end of the 5-year follow-up period. Among 67 patients who had bilateral neovascular maculopathy initially and were examined 5 years later, 33 (49%) were legally blind compared with 13 (12%) of 106 patients who had unilateral neovascular maculopathy initially. In all 13 of the latter group, CNV had developed in the fellow eye.
CONCLUSIONS: Patients with age-related macular degeneration and CNV in one eye are at high risk of legal blindness within 5 years, and, thus, should be followed up carefully to ensure that laser treatment can be applied to CNV in either eye whenever it is likely to improve the visual prognosis.
DESIGN, PATIENTS, AND SETTING: Five-year prospective follow-up study of fellow eyes of 228 patients enrolled in a randomized clinical trial of laser photocoagulation of extrafoveal CNV. Visual acuity was measured and macular photographs were taken at 6-month intervals.
MAIN OUTCOME MEASURES: Five-year change in visual acuity of fellow eyes from baseline, incidence of legal blindness (visual acuity of < or = 20/200 in the better eye), and cumulative incidence of CNV in fellow eyes free of neovascular maculopathy at the time of study enrollment.
RESULTS: Photographically documented CNV developed in 33 (26%) of 128 fellow eyes that were initially free of neovascular maculopathy, and was associated with poor visual acuity at the end of the 5-year follow-up period. Among 67 patients who had bilateral neovascular maculopathy initially and were examined 5 years later, 33 (49%) were legally blind compared with 13 (12%) of 106 patients who had unilateral neovascular maculopathy initially. In all 13 of the latter group, CNV had developed in the fellow eye.
CONCLUSIONS: Patients with age-related macular degeneration and CNV in one eye are at high risk of legal blindness within 5 years, and, thus, should be followed up carefully to ensure that laser treatment can be applied to CNV in either eye whenever it is likely to improve the visual prognosis.
Full text links
Related Resources
Trending Papers
Heart failure with preserved ejection fraction: diagnosis, risk assessment, and treatment.Clinical Research in Cardiology : Official Journal of the German Cardiac Society 2024 April 12
Proximal versus distal diuretics in congestive heart failure.Nephrology, Dialysis, Transplantation 2024 Februrary 30
Efficacy and safety of pharmacotherapy in chronic insomnia: A review of clinical guidelines and case reports.Mental Health Clinician 2023 October
World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.American Journal of Hematology 2024 March 30
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app